2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof

1. A compound of formula (1) or a pharmacologically acceptable salt thereof:

wherein

A is cycloalkyl, a heterocyclic group, aryl or heteroaryl;

Z 1 , Z 2 and Z 3 are one of A)-D):

A) all of Z 1 , Z 2 and Z 3 are carbons;

B) Z 1 is nitrogen, and Z 2 and Z 3 are carbons;

C) Z 2 is nitrogen, and Z 1 and Z 3 are carbons;

D) Z 1 and Z 2 are nitrogens, and Z 3 is carbon;

Z 4 is carbon or nitrogen;

R 1 is halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, cyano, a heterocyclic group, aryl or heteroaryl where the heteroaryl optionally further has at least one substituent selected from alkyl;

R 2 and R 3 are the same or different and each is hydrogen, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy or aryl;

R 4 is hydrogen, alkyl or halogen;

R 5 and R 6 are the same or different and each is —X 1 —R 7a where X 1 is a single bond, linear alkylene, cyclic alkylene, —O—, —O-alkylene- or —CO—, and the linear alkylene, cyclic alkylene or —O-alkylene- for X 1 optionally further has at least one substituent selected from hydroxy, halogen, alkyl, hydroxyalkyl and alkoxy;

R 7a is hydrogen, hydroxy, halogen, alkyl, haloalkyl, hydroxyalkyl, alkoxy, carboxyl, —NR 7b R 7c , alkyleneoxide, cyano, dialkylcarbamoyl, alkylsulfonyl, a heterocyclic group or heteroaryl where R 7b and R 7c are the same or different and each is hydrogen, hydroxy, halogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl or aminoalkyl, and the heterocyclic group or heteroaryl for R 7a optionally further has at least one substituent selected from hydroxy, halogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl and aminoalkyl; and

L 1 is a group selected from 1)-6):

1) —X 2 —;

2) —X 2 —(CH 2 ) n —;

3) —O—X 3 —,

4) —O—(CH 2 ) n—X 3 —;

5) —CO—X 3 —; and

6) —CO—NH—X 3 —

where X 2 is a single bond, linear alkylene, cyclic alkylene, alkenylene, alkynylene, heterocycloalkylene or heteroarylene, X 3 is linear alkylene, cyclic alkylene, alkenylene, alkynylene, heterocycloalkylene or heteroarylene, the linear alkylene, cyclic alkylene, alkenylene or alkynylene for X 2 or X 3 optionally further has at least one substituent selected from alkyl, cycloalkyl, hydroxyalkyl, haloalkyl and alkyleneoxide, the alkyl optionally has at least one substituent selected from aryl and heteroaryl, and n is an integer of 1-3.

2. The compound according to claim 1 , wherein A is aryl or heteroaryl, or a pharmacologically acceptable salt thereof.

3. The compound according to claim 1 , wherein A is a heterocyclic group, or a pharmacologically acceptable salt thereof.

4. The compound according to claim 1 , wherein all of Z 1 , Z 2 and Z 3 are carbons, or a pharmacologically acceptable salt thereof.

5. The compound according to claim 1 , wherein R 1 is halogen, haloalkyl or haloalkoxy, or a pharmacologically acceptable salt thereof.

6. The compound according to claim 5 , wherein R 1 is haloalkoxy, or a pharmacologically acceptable salt thereof.

7. The compound according to claim 1 , wherein R 1 is substituted at the 3-position of the 6-membered ring, or a pharmacologically acceptable salt thereof.

8. The compound according to claim 1 , wherein R 5 and R 6 are the same or different and each is one of

—X 1 —R 7a where X 1 is —O—, and R 7a is alkyl,

—X 1 —R 7a where X 1 is linear alkylene or cyclic alkylene, and R 7a is hydrogen, and

—X 1 —R 7a where X 1 is a single bond, and R 7a is halogen or cyano, or a pharmacologically acceptable salt thereof.

9. The compound according to claim 1 , wherein L 1 is —X 2 — where X 2 is straight chain alkylene or cyclic alkylene, or a pharmacologically acceptable salt thereof.

10. The compound according to claim 9 , wherein L 1 is —X 2 — where X 2 is C1-2 straight chain alkylene or C3-6 cyclic alkylene, or a pharmacologically acceptable salt thereof.

11. The compound according to claim 1 , wherein the cycloalkyl for A is a group selected from:

the heterocyclic group for A is a group selected from:

the aryl for A is:

 and

the heteroaryl for A is a group selected from:

or a pharmacologically acceptable salt thereof.

12. The compound according to claim 2 , wherein A is

or a pharmacologically acceptable salt thereof.

13. The compound according to claim 3 , wherein A is

or a pharmacologically acceptable salt thereof.

14. A compound or a pharmacologically acceptable salt thereof, wherein the compound is one of

2-[6-(3 trifluoromethoxy-benzylamino)-pyridin-3-yl]-3H-benzimidazole-4-carboxylic acid,

2-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-benzoxazole-6-carboxylic acid,

1-methyl-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-1H-indazole-3-carboxylic acid,

5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-1H-indazole-3-carboxylic acid,

3-{3-cyano-2-methoxy-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-phenyl}-propionic acid,

3-{2-chloro-5-[2-(3-trifluoromethoxy-benzylamino)-pyrimidin-5-yl]-phenyl}-propionic acid,

3-{3-cyano-2-methoxy-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-phenyl}-2-methyl-propionic acid,

2-{2-methoxy-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-phenyl}-cyclopropanecarboxylic acid,

(1S,2S)-2-{2-methoxy-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-phenyl}-cyclopropanecarboxylic acid,

2-[5-methoxy-6′-(3-trifluoromethoxy-benzylamino)-[2,3′]bipyridinyl-6-yl]-cyclopropanecarboxylic acid,

(1S,2S)-2-[5-methoxy-6′-(3-trifluoromethoxy-benzylamino)-[2,3′]bipyridinyl-6-yl]-cyclopropanecarboxylic acid,

(1S,2S)-2-{3-methoxy-6-[2-(3-trifluoromethoxy-benzylamino)-pyrimidin-5-yl]-pyridin-2-yl}-cyclopropanecarboxylic acid,

(1S,2S)-2-[5-chloro-6′-(3-trifluoromethoxy-benzylamino)-[2,3′]bipyridinyl-6-yl]-cyclopropanecarboxylic acid,

(1S,2S)-2-[5-ethoxy-6′-(3-trifluoromethoxy-benzylamino)-[2,3′]bipyridinyl-6-yl]-cyclopropanecarboxylic acid,

(1S,2S)-2-[5-methyl-6′-(3-trifluoromethoxy-benzylamino)-[2,3′]bipyridinyl-6-yl]-cyclopropanecarboxylic acid,

3-{2-methoxy-5-[2-(3-trifluoromethoxy-benzylamino)-pyrimidin-5-yl]-phenyl}-propionic acid,

3-{2-methoxy-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-phenyl}-propionic acid,

2-{2-methoxy-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-phenyl}-2-methyl-propionic acid,

2-{3-cyano-2-methoxy-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-phenyl}-2-methyl-propionic acid,

2-chloro-3-(1-methyl-pyrrolidin-3-yloxy)-5-[2-(3-trifluoromethoxy-benzylamino)-pyrimidin-5-yl]-benzoic acid,

2-chloro-3-(pyrrolidin-3-yloxy)-5-[2-(3-trifluoromethoxy-benzylamino)-pyrimidin-5-yl]-benzoic acid,

3-(azetidin-3-yloxy)-2-chloro-5-[2-(3-trifluoromethoxy-benzylamino)-pyrimidin-5-yl]-benzoic acid,

2-chloro-3-(1-methyl-azetidin-3-yloxy)-5-[2-(3-trifluoromethoxy-benzylamino)-pyrimidin-5-yl]-benzoic acid,

2-methoxy-3-pyridin-4-yl-5-[2-(3-trifluoromethoxy-benzylamino)-pyrimidin-5-yl]-benzoic acid,

2-methoxy-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-benzoic acid,

3-fluoro-2-methoxy-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-benzoic acid,

2,3-dimethoxy-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-benzoic acid,

2-chloro-3-methoxy-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-benzoic acid,

3-cyano-2-methoxy-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-benzoic acid,

7-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-1H-indazole-3-carboxylic acid,

4-methoxy-7-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-1H-indazole-3-carboxylic acid,

1-(2-methoxy-ethyl)-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-1H-indazole-3-carboxylic acid,

1-methyl-5-[2-(3-trifluoromethoxy-benzylamino)-pyrimidin-5-yl]-1H-indazole-3-carboxylic acid,

1-(3-methanesulfonyl-propyl)-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-1H-indazole-3-carboxylic acid,

1-(3-cyano-propyl)-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-1H -indazole-3-carboxylic acid,

(E)-3-{3-methyl-2-oxo-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-3-aza -bicyclo[4.1.0]hept-4-en-1-yl}-acrylic acid,

(E)-3-[1-methyl-6-oxo-6′-(3-trifluoromethoxy-benzylamino)-1,6-dihydro -[3,3′]bipyridinyl-5-yl]-acrylic acid,

(1S,2S)-2-[5-isopropoxy-6′-(3-trifluoromethoxy-benzylamino)-[2,3′]bipyridinyl-6-yl]-cyclopropanecarboxylic acid,

3-{3-cyano-2-methoxy-5-[2-(3-trifluoromethoxy-benzylamino)-pyrimidin-5-yl]-phenyl}-propionic acid,

(E)-3-{2-methoxy-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-phenyl}-acrylic acid,

3-{2-methoxy-4-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-phenyl}-propionic acid,

(trans)-2-{2-methoxy-4-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-phenyl}-cyclopropanecarboxylic acid,

(trans)-2-{2-methoxy-5-[2-(3-trifluoromethoxy-benzylamino)-pyrimidin-5-yl]-phenyl}-cyclopropanecarboxylic acid,

3-{2-methoxy-3-oxetan-3-yl-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-phenyl}-propionic acid,

3-{3-cyano-2-methoxy-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-phenyl}-3-methyl-butyric acid,

3-{3-cyano-2-methoxy-5-[2-(3-trifluoromethoxy-benzylamino)-pyrimidin-5-yl]-phenyl}-3-methyl-butyric acid,

(3-{2-methoxy-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-phenyl}-oxetan-3-yl)-acetic acid,

3-{2-methoxy-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-phenyl}-3-methyl-butyric acid,

3-{2,6-dimethoxy-4-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-phenyl}-propionic acid,

3-{2,6-dimethoxy-4-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-phenyl}-2-methyl-propionic acid,

1-[1-methyl-6-oxo-6′-(3-trifluoromethoxy-benzylamino)-1,6-dihydro-[3,3′]bipyridinyl-5-yl]-cyclopropanecarboxylic acid,

2-{3-imidazol-1-ylmethyl-2-methoxy-5-[6-(3-trifluoromethoxy-benzylamino) -pyridin-3-yl]-phenyl}-2-methyl-propionic acid,

{2-methoxy-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-phenyl}-acetic acid,

1-{2-methoxy-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-phenyl}-cyclopropanecarboxylic acid,

2-{2-methoxy-5-[2-(3-trifluoromethoxy-benzylamino)-pyrimidin-5-yl]-phenyl}-2-methyl-propionic acid,

2-[6-methoxy-6′-(3-trifluoromethoxy-benzylamino)-[3,3′]bipyridinyl-5-yl]-2-methyl -propionic acid,

2-[5-methoxy-6′-(3-trifluoromethoxy-benzylamino)-[2,3′]bipyridinyl-6-yl]-2-methyl -propionic acid,

2-{3-hydroxymethyl-2-methoxy-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-phenyl}-2-methyl-propionic acid,

2-{2-methoxy-3-methoxymethyl-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-phenyl}-2-methyl-propionic acid,

2-{2-methoxy-3-[(2,2,2-trifluoro-ethylamino)-methyl]-5-[6-(3-trifluoromethoxy -benzylamino)-pyridin-3-yl]-phenyl}-2-methyl-propionic acid,

2-{3-fluoromethyl-2-methoxy-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-phenyl}-2-methyl-propionic acid,

{2-methoxy-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-phenoxy}-acetic acid,

2-{2-methoxy-5-[6-(3-trifluoromethoxy-benzylamino)-pyridin-3-yl]-phenoxy}-propionic acid,

2-chloro-3-(2-methoxy-ethoxy)-5-[2-(3-trifluoromethoxy-benzylamino)-pyrimidin-5-yl]-benzoic acid,

2-chloro-3-(tetrahydro-pyran-4-yloxy)-5-[2-(3-trifluoromethoxy-benzylamino) -pyrimidin-5-yl]-benzoic acid,

2-chloro-3-[2-(2-oxo-pyrrolidin-1-yl)-ethoxy]-5-[2-(3-trifluoromethoxy -benzylamino)-pyrimidin-5-yl]-benzoic acid,

2-chloro-3-(2-oxo-pyrrolidin-3-yloxy)-5-[2-(3-trifluoromethoxy-benzylamino)-pyrimidin-5-yl]-benzoic acid,

2-chloro-3-(oxetan-3-yloxy)-5-[2-(3-trifluoromethoxy-benzylamino)-pyrimidin-5-yl]-benzoic acid,

2-chloro-3-dimethylcarbamoylmethoxy-5-[2-(3-trifluoromethoxy-benzylamino) -pyrimidin-5-yl]-benzoic acid,

2-chloro-3-(2-dimethylamino-ethoxy)-5-[2-(3-trifluoromethoxy-benzylamino) -pyrimidin-5-yl]-benzoic acid,

2-chloro-3-(2-morpholin-4-yl-ethoxy)-5-[2-(3-trifluoromethoxy-benzylamino) -pyrimidin-5-yl]-benzoic acid,

3-furan-3-yl-2-methoxy-5-[2-(3-trifluoromethoxy-benzylamino)-pyrimidin-5-yl]-benzoic acid,

2-methoxy-5-[2-(3-trifluoromethoxy-benzylamino)-pyrimidin-5-yl]-benzoic acid, and

5-[6-(3-isopropyl-benzylamino)-pyridin-3-yl]-2-methoxy-benzoic acid.

15. A pharmaceutical composition, comprising:

the compound according to claim 1 , or a pharmacologically acceptable salt thereof; and

a pharmaceutically acceptable carrier.

16. The pharmaceutical composition according to claim 15 , wherein the pharmaceutical composition is an ATX inhibitor.

17. A method for treating a disease involving ATX, wherein the disease involving ATX is cancer or tumor including malignant melanoma, brain tumor, neuroblastoma, glioblastoma multiforme, EBV positive Hodgkin lymphoma, glioblastoma, non-small cell lung cancer, lung tumor, breast tumor, ovary tumor, pancreas tumor, prostatic intraepithelial neoplasia, prostate tumor, thyroid tumor, follicular lymphoma, liver tumor, and renal cell carcinoma, fibrosis as including pulmonary fibrosis, hepatic fibrosis, renal fibrosis, and atherosclerosis, asthma, rheumatoid arthritis, type II diabetes-related obesity, acute coronary syndrome, cholestatic pruritus, or an inflammatory disease including inflammatory bowel disease, Crohn's disease, ulcerative colitis, and neuropathic pain, comprising: administering the pharmaceutical composition according to claim 15 , to a patient in need thereof.

18. A pharmaceutical composition, comprising:

the compound according to claim 14 , or a pharmacologically acceptable salt thereof; and

a pharmaceutically acceptable carrier.

19. A method for treating cancer or tumor including malignant melanoma, brain tumor, neuroblastoma, glioblastoma multiforme, EBV positive Hodgkin lymphoma, glioblastoma, non-small cell lung cancer, lung tumor, breast tumor, ovary tumor, pancreas tumor, prostatic intraepithelial neoplasia, prostate tumor, thyroid tumor, follicular lymphoma, liver tumor, and renal cell carcinoma, fibrosis including pulmonary fibrosis, hepatic fibrosis, renal fibrosis, and atherosclerosis, asthma, rheumatoid arthritis, type II diabetes-related obesity, acute coronary syndrome, cholestatic pruritus, or an inflammatory disease including inflammatory bowel disease, Crohn's disease, ulcerative colitis, and neuropathic pain, comprising:

administering the pharmaceutical composition according to claim 18 to a patient in need thereof.